Aspirin use among adults in the U.S.: Results of a national survey

American Journal of Preventive Medicine

Volumn 48, Issue 5, 2015, Pages 501-508

  Williams, Craig D ^a   Chan, Andrew T ^b   Elman, Miriam R ^a   Kristensen, Alyson H ^c   Miser, W Fred ^d   Pignone, Michael P ^e   Stafford, Randall S ^f   McGregor, Jessina C ^a  

^a OREGON STATE UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Partnership for Prevention   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONSUMER HEALTH INFORMATION; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GROUPS BY AGE; HEALTH SURVEY; HUMAN; HYPERTENSION; KNOWLEDGE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PRIMARY PREVENTION; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; SELF EVALUATION; SMOKING; UNITED STATES; ATTITUDE TO HEALTH; MIDDLE AGED; STATISTICAL MODEL;

AGED; ASPIRIN; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SURVEYS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PRIMARY PREVENTION; UNITED STATES;

EID: 84928258837     PISSN: 07493797     EISSN: 18732607     Source Type: Journal    
DOI: 10.1016/j.amepre.2014.11.005     Document Type: Article

References (9)

1. C. Baigent, L. Blackwell, and R. Collins Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 9678 2009 1849 1860 10.1016/S0140-6736(09)60503-1
2. U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 150 6 2009 396 404 10.7326/0003-4819-150-6-200903170-00008
3. J. Perk, G. De Backer, and H. Gohlke European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur Heart J 33 13 2012 1635 1701 10.1093/eurheartj/ehs092
4. U.S. Food and Drug Administration. Safe daily use of aspirin 2012 www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/understandingover-the-countermedicines/safedailyuseofaspirin/default.htm
5. A.M. Algra, and P.M. Rothwell Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials Lancet Oncol 13 5 2012 518 527 10.1016/S1470-2045(12)70112-2
6. A.T. Chan, and N.R. Cook Are we ready to recommend aspirin for cancer prevention? Lancet 379 9826 2012 1569 1571 10.1016/S0140-6736(11)61654-1
7. A.M. Algra Towards a global brief on aspirin Lancet 381 9875 2013 1344 1345 10.1016/S0140-6736(13)60772-2
8. Y. Zhou, D.M. Boudreau, and A.N. Freedman Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population Pharmacoepidemiol Drug Saf 23 1 2014 43 50 10.1002/pds.3463
9. M. Pignone, G.K. Anderson, and K. Binns Aspirin use among adults aged 40 and older in the United States: results of a national survey Am J Prev Med 32 5 2007 403 407 10.1016/j.amepre.2007.01.010